On April 28, 2026, in New Taipei City, Taiwan, Jyong Biotech Ltd. (Nasdaq: MENS) revealed its progress in market access strategies for plant-based drugs Botreso ® and PCP. The biotechnology company, known for its focus on innovative plant-derived therapeutics, conducted an analysis of the drugs' clinical efficacy and competitive edge. This step signifies a significant development in the commercialization of these medications.